Prognostic factors in Crohn’s disease: a systematic review

##plugins.themes.academic_pro.article.sidebar##

Published May 3, 2013
Download
pdf
Vol. 91 No. 4 (2013): Issue Apr 2013

##plugins.themes.academic_pro.article.main##

S. Karoui
M. Serghini
A. Dachraoui
J. Boubaker
A. Filali

Abstract

Background: The natural history of Crohn’s disease is associated with several factors that affect the prognostic of the patients.
aims: To determine the most prognostic factors in Crohn’s disease, based on a systematic review. methods: Literature review.
results: The most important factors to consider in patients with Crohn’s disease are the need for immunosuppressive therapy, the need for intestinal resection and disabling disease. Prognostic factors for these events are ileal involvement, perianal disease and initial treatment by corticosteroid. Other factors such young age, CRP level and smoking status, has not been found in all population-based studies. Protective role of anti-TNF drugs is strongly suggested but need to be confirmed in further studies.
Conclusion: In a selected subgroup of patients with Crohn’s disease characterized by the presence of these prognostic markers, the “topdown” strategy can be proposed.

Keywords:

Crohn's disease , Prognosis

##plugins.themes.academic_pro.article.details##

References

  1. Vermeire S, Van Assche G, Rutgeerts P. Altering the natural history of Crohn's disease. Evidence for and against current strategies. Aliment Pharmacol Ther 2006;25:3-12.
  2. Dignass A, Van Assche G, Lindsay JO et al. The second European evidence-based consensus of the diagnosis and management of Crohn's disease: current management. J Crohn Colitis 2010;4:28-62.
  3. D'Haens G, Baert F, Van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial. Lancet 2008;371:660-67.
  4. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
  5. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010;105:289-97.
  6. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006;130:650-56.
  7. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6- mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med 1995;123:132-42.
  8. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA. Impact of azathioprine and TNF antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut. 2011;60:930-6.
  9. Jacobstein DA, Manula P, Markowitz JE, Leonard M, Baldassano RN. Predictors of immunomodulator use as early therapy in pediatric Crohn's disease. J Clin Gastroenterol 2006;40:145-48.
  10. Karoui S, Bibani N, Serghini M, et al. Predictive factors of azathioprine prescription in adult patients with Crohn's disease. Hepatogastroenterology 2010;57:283-87.
  11. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231:38-45.
  12. Lakatos PL, Kiss LS. Is the disease course predictable in inflammatory bowel disease? World J Gastroenterol 2010;16:2591-99.
  13. Siphroudis L, Mortaji A, Mary JY, Juguet F, Bretagne JF, Gosselin M. Anal lesions: any significant prognosis in Crohn's disease ? Eur J Gastroenterol Hepatol 1997;9:239-43.
  14. Veloso FT, Ferreira JT, Barros L, Almeida S. Clinical outcomes of Crohn's disease: analysis according to the Vienna classification and clinical activity. Inflamm Bowel Dis 2001;7:306-13.
  15. Henckaerts L, Van Steen K, Verstreken I et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009;7:972-80.
  16. Greenstein AJ, Lachman P, Sachar DB et al. Perforating and non perforating indications for repeated operation in Crohn's disease: evidence for two clinical forms. Gut 1988;29:588-92.
  17. Karoui S, Bibani N, Serghini M et al. Can we predict the risk of surgery in patients with Crohn's disease according to the phenotype of the disease? Gut 2010;59(Suppl III):A13.
  18. Wolters FL, Russel MG, Sijbrandij J et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006;55:1124-30.
  19. Chow DKL, Sung JJY, Wu JCY, Tsoi KKF, Leng RWL, Chan FKL. Upper gastrointestinal tract phenotype of Crohn's disease is associated with early surgery and further hospitalization. Inflamm Bowel Dis 2009;15:551-57.
  20. Vasilauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunogically homogenous subgroups with distinct clinical characteristics. Gut 2000;47:487-96.
  21. Arnott ID, Landers CJ, Nimmo EJ et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004;99:2376-84.
  22. Ferrante M, Henckaerts L, Joosens M et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007;56:1394-403.
  23. Henriksen M, Jahnsen J, Lygren I et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease: Results from a prospective population-based study. Gut 2008;57:1518-23.
  24. Allez M, Lémann M, Bonnet J, Cattan P, Jian R, Modigliani R. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002;97:947-53.
  25. Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian populationbased cohort. Gastroenterology 2007;133:412-22.
  26. 26-Rutgeerts P, Diamond D, Bala M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42.
  27. Jones DW, Finlayson SR. Trends of surgery in Crohn's disease in the era of infliximab. Ann Surg 2010;252:307-12.
  28. Ramadas AV, Gunesh S, Thomas GAO, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010;59:1200-206.
  29. Loly C, Belaïche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008;43:948-54.
  30. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010;139:1147-55.
  31. Louis E, Michel V, Hugot JP et al. Early development of structuring or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking, but not by NOD2/CARD15 genotype. Gut 2003;52:552-57.
  32. Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996;110:424-31.